File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management

TitleClinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
Authors
KeywordsChinese medicine
Herbal medicine
Diabetic nephropathy
Diabetic kidney disease
Signaling pathway
Issue Date2021
PublisherElsevier, published in association with Institute of Materia Medica and Chinese Pharmaceutical Association. The Journal's web site is located at http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b
Citation
Acta Pharmaceutica Sinica B, 2021, v. 11 n. 9, p. 2749-2767 How to Cite?
AbstractDiabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.
Persistent Identifierhttp://hdl.handle.net/10722/305129
ISSN
2023 Impact Factor: 14.7
2023 SCImago Journal Rankings: 3.035
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTANG, G-
dc.contributor.authorLi, S-
dc.contributor.authorZHANG, C-
dc.contributor.authorChen, H-
dc.contributor.authorWang, N-
dc.contributor.authorFeng, Y-
dc.date.accessioned2021-10-05T02:40:08Z-
dc.date.available2021-10-05T02:40:08Z-
dc.date.issued2021-
dc.identifier.citationActa Pharmaceutica Sinica B, 2021, v. 11 n. 9, p. 2749-2767-
dc.identifier.issn2211-3835-
dc.identifier.urihttp://hdl.handle.net/10722/305129-
dc.description.abstractDiabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.-
dc.languageeng-
dc.publisherElsevier, published in association with Institute of Materia Medica and Chinese Pharmaceutical Association. The Journal's web site is located at http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b-
dc.relation.ispartofActa Pharmaceutica Sinica B-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectChinese medicine-
dc.subjectHerbal medicine-
dc.subjectDiabetic nephropathy-
dc.subjectDiabetic kidney disease-
dc.subjectSignaling pathway-
dc.titleClinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management-
dc.typeArticle-
dc.identifier.emailChen, H: haiyong@hku.hk-
dc.identifier.emailWang, N: ckwang@hku.hk-
dc.identifier.emailFeng, Y: yfeng@hku.hk-
dc.identifier.authorityChen, H=rp01923-
dc.identifier.authorityWang, N=rp02075-
dc.identifier.authorityFeng, Y=rp00466-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.apsb.2020.12.020-
dc.identifier.pmid34589395-
dc.identifier.pmcidPMC8463270-
dc.identifier.scopuseid_2-s2.0-85105062081-
dc.identifier.hkuros326193-
dc.identifier.volume11-
dc.identifier.issue9-
dc.identifier.spage2749-
dc.identifier.epage2767-
dc.identifier.isiWOS:000701202400013-
dc.publisher.placeChina-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats